Daiwa Securities Group Inc. Increases Stock Position in Cencora, Inc. $COR

Daiwa Securities Group Inc. grew its holdings in Cencora, Inc. (NYSE:COR) by 53.0% during the 2nd quarter, Holdings Channel reports. The firm owned 38,063 shares of the company’s stock after buying an additional 13,191 shares during the period. Daiwa Securities Group Inc.’s holdings in Cencora were worth $11,413,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the stock. Baader Bank Aktiengesellschaft boosted its stake in shares of Cencora by 318.5% during the 2nd quarter. Baader Bank Aktiengesellschaft now owns 4,336 shares of the company’s stock worth $1,300,000 after purchasing an additional 3,300 shares during the last quarter. Voleon Capital Management LP acquired a new position in shares of Cencora in the first quarter valued at approximately $3,111,000. Focus Partners Wealth lifted its stake in shares of Cencora by 25.8% during the first quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock valued at $1,589,000 after buying an additional 1,171 shares during the period. Acadian Asset Management LLC lifted its stake in shares of Cencora by 947.5% during the second quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock valued at $77,069,000 after buying an additional 232,539 shares during the period. Finally, Martin Capital Partners LLC boosted its position in Cencora by 205.2% during the second quarter. Martin Capital Partners LLC now owns 3,784 shares of the company’s stock worth $1,135,000 after acquiring an additional 2,544 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Price Performance

Shares of Cencora stock opened at $340.63 on Thursday. The business’s fifty day moving average price is $341.71 and its 200 day moving average price is $310.60. Cencora, Inc. has a twelve month low of $223.92 and a twelve month high of $377.54. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32. The stock has a market capitalization of $66.08 billion, a P/E ratio of 42.85, a PEG ratio of 1.60 and a beta of 0.63.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.79 by $0.05. The company had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The firm’s revenue was up 5.9% on a year-over-year basis. During the same period in the prior year, the firm posted $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were issued a $0.60 dividend. The ex-dividend date was Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a yield of 0.7%. Cencora’s payout ratio is 30.19%.

Insider Buying and Selling

In other news, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction on Monday, October 20th. The shares were sold at an average price of $326.80, for a total value of $1,665,699.60. Following the transaction, the chief executive officer owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. This trade represents a 11.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Chairman Steven H. Collis sold 31,350 shares of Cencora stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. The trade was a 9.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 46,640 shares of company stock worth $14,099,338. 10.80% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have weighed in on COR shares. Barclays initiated coverage on Cencora in a report on Monday. They issued an “overweight” rating and a $400.00 price target for the company. Mizuho lifted their price objective on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Wells Fargo & Company upped their target price on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. Evercore ISI set a $400.00 price target on Cencora and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Finally, JPMorgan Chase & Co. lifted their price target on Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Nine analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $373.50.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.